Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data Patients with stage I-III colon cancer treated with upfront ...

The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.

In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in ...

Table 1. Summary of clinicopathologic features evaluated in the different models to predict MMR deficiency ...

Tecentriq plus chemotherapy reduced recurrence or death risk by 50% in stage III colorectal cancer with deficient mismatch repair. The combination therapy achieved a 3-year disease-free survival rate ...

CHICAGO -- The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients who received immunotherapy in addition to adjuvant chemotherapy, ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...

Maureen Sideris was driving to Maine for a wedding when she realized she couldn’t swallow the sandwich she was having for lunch. The 71-year-old was soon diagnosed with gastroesophageal cancer. It was ...